Trial of Leptin Administration After Roux-en-Y Gastric Bypass

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2012

Study Completion Date

July 31, 2014

Conditions
Overweight
Interventions
DRUG

Leptin

Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day

OTHER

Placebo

Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day

Trial Locations (1)

10032

Columbia University Medical Center, New York

Sponsors
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Columbia University

OTHER

NCT00710814 - Trial of Leptin Administration After Roux-en-Y Gastric Bypass | Biotech Hunter | Biotech Hunter